Ginkgo Bioworks (NYSE:DNA) Stock: Insider Steven Coen Sells 2,403 Shares

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) insider Steven Coen sold 2,403 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $15.00, for a total transaction of $36,045.00. Following the completion of the sale, the insider directly owned 49,448 shares of the company’s stock, valued at $741,720. This trade represents a 4.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

Ginkgo Bioworks Stock Down 0.8%

DNA opened at $11.38 on Friday. The firm’s 50 day moving average is $8.46 and its 200-day moving average is $8.33. Ginkgo Bioworks Holdings, Inc. has a 52-week low of $5.37 and a 52-week high of $18.22. The firm has a market capitalization of $765.99 million, a P/E ratio of -2.27 and a beta of 1.79.

Ginkgo Bioworks (NYSE:DNA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.75) earnings per share for the quarter, beating the consensus estimate of ($0.90) by $0.15. Ginkgo Bioworks had a negative net margin of 259.96% and a negative return on equity of 60.27%. The business had revenue of $20.16 million during the quarter, compared to the consensus estimate of $24.05 million. Equities analysts expect that Ginkgo Bioworks Holdings, Inc. will post -3.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently issued reports on DNA shares. Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. BTIG Research reissued a “sell” rating and issued a $5.00 price target on shares of Ginkgo Bioworks in a report on Friday, September 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Ginkgo Bioworks in a research note on Friday, July 17th. Zacks Research upgraded Ginkgo Bioworks to a “hold” rating in a report on Monday, August 17th. Finally, TD Cowen lowered Ginkgo Bioworks from a “buy” rating to a “hold” rating and cut their target price for the company from $12.00 to $9.00 in a research report on Friday, August 7th. Two investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $6.33.

Institutional Investors Weigh In On Ginkgo Bioworks

A number of institutional investors have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its position in shares of Ginkgo Bioworks by 1.8% during the 1st quarter. Bank of New York Mellon Corp now owns 123,959 shares of the company’s stock valued at $760,000 after buying an additional 2,178 shares during the last quarter. Strategic Advocates LLC lifted its holdings in Ginkgo Bioworks by 808.9% in the fourth quarter. Strategic Advocates LLC now owns 4,381 shares of the company’s stock worth $36,000 after acquiring an additional 3,899 shares during the last quarter. Integrated Wealth Concepts LLC acquired a new position in Ginkgo Bioworks in the second quarter valued at approximately $50,000. Arizona State Retirement System bought a new position in shares of Ginkgo Bioworks during the second quarter valued at approximately $102,000. Finally, Entropy Technologies LP bought a new position in shares of Ginkgo Bioworks during the first quarter valued at approximately $67,000. Institutional investors and hedge funds own 78.63% of the company’s stock.

Key Ginkgo Bioworks News

Here are the key news stories impacting Ginkgo Bioworks this week:

• Positive Sentiment: NSF partnership expands strategic visibility: Ginkgo will provide in-kind access to its autonomous Boston laboratory, cloud-lab time and protein-testing services to researchers participating in the National Science Foundation’s X-Labs program. The decade-long initiative is backed by $1.5 billion and could showcase Ginkgo’s automation and biological-engineering platform to new researchers and potential customers, although the announcement does not specify immediate revenue. Ginkgo Bioworks to Provide Autonomous Lab Access to NSF X-Labs Researchers
• Positive Sentiment: Autonomous-lab capabilities strengthened: Ginkgo integrated Araceli Biosciences’ Endeavor high-content imaging system into its Nebula lab-in-the-loop platform. Faster, higher-volume cellular imaging could improve data generation and research productivity, potentially making Ginkgo’s services more attractive to biotech customers. Araceli Biosciences and Ginkgo Bioworks Bring Cellular Imaging at Scale to Nebula
• Neutral Sentiment: Institutional ownership remains substantial: Hedge funds and other institutions own about 78.6% of DNA, with several firms recently initiating or increasing positions. This may provide some shareholder support, though it does not change the company’s underlying operating performance.
• Negative Sentiment: Valuation and profitability concerns persist: An analysis argued that DNA’s valuation has risen faster than its business fundamentals. Ginkgo remains deeply unprofitable, with a negative net margin, and its latest revenue of $20.16 million fell short of the $24.05 million estimate. The stock is also trading well above the reported analyst consensus target of $6.33. Ginkgo Bioworks: The Valuation Has Outrun the Business
• Negative Sentiment: Insider selling adds a cautionary signal: Insider Steven Coen sold 2,403 shares for approximately $36,045, reducing his position by 4.63%. The transaction is relatively small, but insider selling can weigh on sentiment when the company is already facing valuation concerns. Insider Selling: Ginkgo Bioworks Insider Sells 2,403 Shares
• Negative Sentiment: Analyst sentiment remains bearish: Oppenheimer and BTIG Research cited $5 price targets, while TD Cowen downgraded DNA to Hold with a $9 target. The consensus rating was reported as Reduce.

About Ginkgo Bioworks

Ginkgo Bioworks, Inc is a biotechnology company that develops biological engineering technologies and services. Its platform is designed to help customers program cells and microorganisms to produce products or perform functions for applications in areas such as pharmaceuticals, agriculture, food, chemicals and materials.

The company combines biological research, laboratory automation, genetic engineering, data analysis and software through its cell-programming platform and foundry operations.